Therapeutic Outcomes and Clinical Features of Advanced Non-Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study
- Mazzaschi, Giulia
- Perrone, Fabiana
- Minari, Roberta
- Verzè, Michela
- Azzoni, Cinzia
- Bottarelli, Lorena
- Pluchino, Monica
- Armillotta, Maria Pia
- Ubaldi, Annalisa
- Altimari, Annalisa
- Gruppioni, Elisa
- Sperandi, Francesca
- Andrini, Elisa
- Guaitoli, Giorgia
- Bettelli, Stefania
- Longo, Lucia
- Bertolini, Federica
- Barbieri, Fausto
- Pagano, Maria
- Bonelli, Candida
- Tagliavini, Elena
- Nicoli, Davide
- Ubiali, Alessandro
- Zangrandi, Adriano
- Trubini, Serena
- Proietto, Manuela
- Gnetti, Letizia
- Tiseo, Marcello
DOIAbstract
Targeting Kirsten Rat Sarcoma (KRAS) has been deemed impossible for long time, but new drugs have recently demonstrated promising results. Evidence on the outcome of KRAS-mutant advanced-NSCLC treated with new standard regimens are still scarce. Thus, we aimed at assessing the incidence and clinical impact of KRAS mutations in a real-life population of advanced-NSCLC, exploring the prognostic significance of distinct alterations
Add to ORKG